2026-05-10T16:19:53Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/231282024-11-28T16:44:22Zcom_20.500.12105_2173com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19597col_20.500.12105_16958col_20.500.12105_16960col_20.500.12105_16975col_20.500.12105_16982col_20.500.12105_16984col_20.500.12105_16990
Repisalud
author
Sargas, Claudia
author
Ayala, Rosa
author
Larráyoz, María J
author
Chillón, María C
author
Rodriguez-Arboli, Eduardo
author
Bilbao, Cristina
author
Prados de la Torre, Esther
author
Martínez-Cuadrón, David
author
Rodríguez-Veiga, Rebeca
author
Boluda, Blanca
author
Gil, Cristina
author
Bernal, Teresa
author
Bergua, Juan
author
Algarra, Lorenzo
author
Tormo, Mar
author
Martínez-Sánchez, Pilar
author
Soria, Elena
author
Serrano, Josefina
author
Alonso-Dominguez, Juan M
author
García, Raimundo
author
Amigo, María Luz
author
Herrera-Puente, Pilar
author
Sayas, María J
author
Lavilla-Rubira, Esperanza
author
Martinez-Lopez, Joaquin
author
Calasanz, María J
author
García-Sanz, Ramón
author
Pérez-Simón, José A
author
Gómez Casares, María T
author
Sánchez-García, Joaquín
author
Barragán, Eva
author
Montesinos, Pau
author
PETHEMA cooperative study group
funder
Ministerio de Ciencia, Innovación y Universidades (España)
funder
Instituto de Salud Carlos III
2024-09-16T08:17:18Z
2024-09-16T08:17:18Z
2023-05-12
Blood Cancer J . 2023;13(1):77.
10.1038/s41408-023-00835-5
2044-5385
Blood cancer journal
37173322
https://hdl.handle.net/20.500.12105/23128
Next-Generation Sequencing is needed for the accurate genetic risk stratification of acute myeloid leukemia according to European LeukemiaNet (ELN) guidelines. We validated and compared the 2022 ELN risk classification in a real-life cohort of 546 intensively and 379 non-intensively treated patients. Among fit patients, those aged ?65 years old showed worse OS than younger regardless risk classification. Compared with the 2017 classification, 14.5% of fit patients changed the risk with the 2022 classification, increasing the high-risk group from 44.3% to 51.8%. 3.7% and 0.9% FLT3-ITD mutated patients were removed from the favorable and adverse 2017 categories respectively to 2022 intermediate risk group. We suggest that midostaurin therapy could be a predictor for 3 years OS (85.2% with vs. 54.8% without midostaurin, P = 0.04). Forty-seven (8.6%) patients from the 2017 intermediate group were assigned to the 2022 adverse-risk group as they harbored myelodysplasia (MDS)-related mutations. Patients with one MDS-related mutation did not reach median OS, while patients with ?2 mutations had 13.6 months median OS (P = 0.002). Patients with TP53 � complex karyotype or inv(3) had a dismal prognosis (7.1 months median OS). We validate the prognostic utility of the 2022 ELN classification in a real-life setting providing supportive evidences to improve risk stratification guidelines.
eng
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
research article